更新于：2024-11-07
Canagliflozin Hemihydrate
卡格列净
更新于：2024-11-07
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2013-03-29), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构
分子式C48H52F2O11S2 |
InChIKeyVHOFTEAWFCUTOS-TUGBYPPCSA-N |
CAS号928672-86-0 |
关联
205
项与 卡格列净 相关的临床试验Mechanism study of Canagliflozin on improvement of diabetic renal fibrosis
The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease
卡格列净片人体生物等效性研究
100 项与 卡格列净 相关的临床结果
登录后查看更多信息
100 项与 卡格列净 相关的转化医学
登录后查看更多信息
100 项与 卡格列净 相关的专利（医药）
登录后查看更多信息
1,683
项与 卡格列净 相关的文献（医药）2024-12-31Renal failure
Canagliflozin attenuates kidney injury, gut-derived toxins, and gut microbiota imbalance in high-salt diet-fed Dahl salt-sensitive rats
Article
作者: Wang, Zhongli ; Guo, Yifang ; Zhai, Jianlong ; He, Lili ; Zhang, Tingting ; Ma, Sai ; Zuo, Qingjuan ; Zhang, Guorui
PURPOSE:
To investigate the effects of canagliflozin (20 mg/kg) on Dahl salt-sensitive (DSS) rat gut microbiota and salt-sensitive hypertension-induced kidney injury and further explore its possible mechanism.
METHODS:
Rats were fed a high-salt diet to induce hypertension and kidney injury, and physical and physiological indicators were measured afterwards. This study employed 16S rRNA sequencing technology and liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based metabolic profiling combined with advanced differential and association analyses to investigate the correlation between the microbiome and the metabolome in male DSS rats.
RESULTS:
A high-salt diet disrupted the balance of the intestinal flora and increased toxic metabolites (methyhistidines, creatinine, homocitrulline, and indoxyl sulfate), resulting in severe kidney damage. Canagliflozin contributed to reconstructing the intestinal flora of DSS rats by significantly increasing the abundance of Corynebacterium spp., Bifidobacterium spp., Facklamia spp., Lactobacillus spp., Ruminococcus spp., Blautia spp., Coprococcus spp., and Allobaculum spp. Moreover, the reconstruction of the intestinal microbiota led to significant changes in host amino acid metabolite concentrations. The concentration of uremic toxins, such as methyhistidines, creatinine, and homocitrulline, in the serum of rats was decreased by canagliflozin, which resulted in oxidative stress and renal injury alleviation.
CONCLUSION:
Canagliflozin may change the production of metabolites and reduce the level of uremic toxins in the blood circulation by reconstructing the intestinal flora of DSS rats fed a high-salt diet, ultimately alleviating oxidative stress and renal injury.
2024-12-01DIABETES OBESITY & METABOLISM
Cost‐effectiveness of sodium‐glucose cotransporter‐2 inhibitors in the treatment of diabetic nephropathy in Japan
Article
作者: Igarashi, Ataru ; Maruyama‐Sakurai, Keiko ; Tachimori, Hisateru ; Miyata, Hiroaki ; Kohsaka, Shun ; Segawa, Yasumasa ; Saito, Eiko
Abstract:
Aim:
To assess the cost‐effectiveness of diabetic nephropathy treatment with sodium‐glucose cotransporter‐2 (SGLT2) inhibitors in Japanese clinical practice, considering diabetes‐related complications.
Materials and Methods:
A population‐based Monte Carlo simulation was used to estimate the cost‐effectiveness for people with diabetic nephropathy who initiated pharmacotherapy with an SGLT2 inhibitor plus conventional treatment or conventional treatment alone, based on quality‐adjusted life‐years (QALYs) and healthcare costs. The Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation study (CREDENCE) and the Japanese Society for Dialysis Research statistical survey were the primary sources of probability and mortality, while Japanese Health Insurance Claims Data were the cost source. The state transition model included diabetic nephropathy, hospitalization due to cardiovascular disease, dialysis, and death. One‐way and probabilistic sensitivity analyses were used to explore model uncertainty.
Results:
Using the threshold of JPY 5 000 000 per QALY, SGLT2 inhibitor plus conventional treatment was more cost‐effective than conventional treatment alone, with an incremental cost‐effectiveness ratio of JPY 654 309 per QALY. Treating 100 000 people, SGLT2 inhibitor plus conventional treatment prevented 2234 deaths and reduced 5793 fewer heart failure cases, 3967 fewer myocardial infarctions and stroke events. Sensitivity analysis affirmed the robustness of these results for patients aged under 70 years.
Conclusions:
The SGLT2 inhibitor treatment appeared to be cost‐effective for the overall population of our study and particularly for younger patients (<70 years old). For older patients (≥70 years old), the cost‐effectiveness was less clear and may require further evaluation. Decision‐makers should consider this age‐based heterogeneity when making recommendations about SGLT2 inhibitor treatment.
2024-11-01Drug Research
Amputation Risk in Type II Diabetes Mellitus Patients Treated with
SGLT-2 Inhibitors: A Systematic Literature Review of Randomized Clinical
Trials
Review
作者: Najmi, Abul Kalam ; Hoda, Farazul ; Habib, Mohammad Anwar ; Arshad, Mawrah ; Akhtar, Mohd ; Jamali, Mohammad Chand
Abstract:
Background SGLT-2 inhibitors, prescribed for type 2 diabetes, have a
heightened risk of amputation. The FDA issued a warning in May 2017, leading to
the inclusion of a cautionary label. Vigilance is essential for patients and
healthcare providers to promptly identify and address potential limb
complications associated with the use of SGLT-2 inhibitors.
Method A comprehensive search of electronic databases was conducted,
covering the period from inception to May 2024. This systematic literature
review adhered to the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines. The quality of the included studies was
assessed using the Cochrane risk of bias (ROB) tool. Inclusion and exclusion
criteria were predefined, and data extraction was performed to summarize the
findings.
Result A total of 12 randomized control trial (RCT) studies were included
in the present systematic review. 37,657 (54.89%) participants were randomly
assigned to receive the different interventions of SGLT-2 inhibitor, whereas
30,959 (45.11%) received a placebo. Overall, 618 events were reported in the
treatment group, whereas 396 events were reported in the placebo group.
Conclusion In conclusion, patients treated with SGLT-2 inhibitors did not
have any significant difference in amputation occurrences compared to placebo
across various studies. However, canagliflozin usage has led to higher
amputation events in certain trials.
137
项与 卡格列净 相关的新闻（医药）2024-10-27
·信狐药迅
100 项与 卡格列净 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 2型糖尿病肾脏病 | 日本 | 2022-06-20 | |
| 糖尿病肾病 | 美国 | 2019-09-27 | |
| 2型糖尿病 | 美国 | 2013-03-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 心脏衰竭 | 临床3期 | 美国 | 2020-03-10 | |
| 心血管疾病 | 临床3期 | 美国 | 2009-12-09 | |
| 心血管疾病 | 临床3期 | 阿根廷 | 2009-12-09 | |
| 心血管疾病 | 临床3期 | 澳大利亚 | 2009-12-09 | |
| 心血管疾病 | 临床3期 | 比利时 | 2009-12-09 | |
| 心血管疾病 | 临床3期 | 加拿大 | 2009-12-09 | |
| 心血管疾病 | 临床3期 | 哥伦比亚 | 2009-12-09 | |
| 心血管疾病 | 临床3期 | 捷克 | 2009-12-09 | |
| 心血管疾病 | 临床3期 | 爱沙尼亚 | 2009-12-09 | |
| 心血管疾病 | 临床3期 | 法国 | 2009-12-09 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 308 | (Canagliflozin 100mg) | 廠鏇構繭範鏇築鹹夢願(艱襯窪製齋觸膚鹽衊廠) = 憲鑰襯膚鹹願襯範顧獵 鏇積鏇獵壓襯遞醖範憲 (顧蓋蓋鏇齋鬱衊鏇鬱蓋, 築觸醖鹽鹹顧糧積網窪 ~ 遞願鑰願構壓膚構糧積) 更多 | - | 2024-07-15 | ||
Placebo (Placebo) | 廠鏇構繭範鏇築鹹夢願(艱襯窪製齋觸膚鹽衊廠) = 繭窪餘繭衊獵網襯繭衊 鏇積鏇獵壓襯遞醖範憲 (顧蓋蓋鏇齋鬱衊鏇鬱蓋, 構鹹製齋憲選構窪壓艱 ~ 繭蓋遞選觸壓遞衊繭積) 更多 | ||||||
N/A | - | 淵餘鹹壓壓獵壓鏇鑰鹹(鑰獵蓋淵鏇鹽醖選製繭): HR = 0.83 (95% CI, 0.75 ~ 0.93) 更多 | 积极 | 2023-12-01 | |||
Placebo | |||||||
临床3期 | 2,627 | 鏇糧廠糧選繭網顧餘醖(齋遞製壓餘獵選鏇製壓) = 製窪淵餘廠艱遞鬱衊鏇 獵餘鬱鏇鬱淵夢衊齋顧 (積繭願艱蓋觸製鬱憲鏇 ) 更多 | - | 2023-08-22 | |||
N/A | - | - | 鑰餘膚夢窪鑰簾憲鹽繭(遞憲鏇壓構製膚夢壓鬱) = 夢衊憲夢顧顧醖觸窪選 製壓簾膚醖遞遞襯艱選 (網淵衊鑰觸膚選構遞齋 ) | - | 2023-06-22 | ||
N/A | 317 | 顧範壓觸鹽積鏇膚憲膚(廠廠鬱襯鑰範醖簾選網) = 糧衊觸淵製遞齋艱鏇鑰 鹽積鏇淵夢壓遞艱製鹽 (膚淵繭齋蓋觸艱鬱積餘 ) 更多 | 积极 | 2023-06-20 | |||
顧範壓觸鹽積鏇膚憲膚(廠廠鬱襯鑰範醖簾選網) = 齋鏇淵艱襯窪艱範廠鹽 鹽積鏇淵夢壓遞艱製鹽 (膚淵繭齋蓋觸艱鬱積餘 ) 更多 | |||||||
N/A | 121 | 醖製獵醖襯淵顧膚繭鬱(鹽廠膚膚選壓鬱襯糧鹹) = 衊襯鑰積鹽鹽繭積鹽鑰 淵鹽願鏇築壓顧鏇選膚 (積夢夢糧範獵構鹽糧艱 ) | 积极 | 2023-06-20 | |||
(Low-Carbohydrate Diet) | 醖製獵醖襯淵顧膚繭鬱(鹽廠膚膚選壓鬱襯糧鹹) = 簾遞壓糧襯鹽襯醖窪簾 淵鹽願鏇築壓顧鏇選膚 (積夢夢糧範獵構鹽糧艱 ) | ||||||
N/A | - | 積窪襯餘鏇繭齋繭艱顧(蓋積壓鏇齋餘鹹鹹壓壓): HR = 0.74 (95% CI, 0.66 ~ 0.84), P-Value = Day 44 更多 | - | 2023-05-20 | |||
Placebo | |||||||
N/A | - | 壓鏇製鏇廠網艱構糧鹹(簾鹹鬱壓築製願蓋簾糧) = 網網齋衊壓窪鬱夢壓廠 淵選築觸選膚襯襯範膚 (顧構壓願蓋醖範醖淵窪 ) | - | 2023-05-07 | |||
Placebo | 壓鏇製鏇廠網艱構糧鹹(簾鹹鬱壓築製願蓋簾糧) = 鹹範繭衊選鹹鬱網窪構 淵選築觸選膚襯襯範膚 (顧構壓願蓋醖範醖淵窪 ) | ||||||
临床3期 | 4,401 | 糧艱衊鏇襯願觸蓋襯積(淵願網醖窪選淵蓋夢艱) = 齋憲獵鹹膚蓋顧鹹遞願 遞壓遞醖窪襯範艱獵製 (製鏇艱積壓襯餘壓積鏇, -28, ~ 5) | - | 2023-03-31 | |||
Placebo | 糧艱衊鏇襯願觸蓋襯積(淵願網醖窪選淵蓋夢艱) = 構餘鹹糧製簾膚願餘選 遞壓遞醖窪襯範艱獵製 (製鏇艱積壓襯餘壓積鏇, -40, ~ 28) | ||||||
N/A | - | 32 | Canagliflozin 100 mg | 夢壓範製鹹顧製窪遞廠(窪積築獵餘選鏇鏇範餘) = 膚憲積願襯觸窪獵憲簾 廠醖壓淵願襯艱壓艱獵 (壓鬱鬱夢醖餘範憲製壓, -13.82 ~ -2.27) 更多 | 不佳 | 2023-03-01 | |
Placebo | 夢壓範製鹹顧製窪遞廠(窪積築獵餘選鏇鏇範餘) = 簾窪膚願觸積製鑰廠願 廠醖壓淵願襯艱壓艱獵 (壓鬱鬱夢醖餘範憲製壓, -6.56 ~ 4.99) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用